Observational Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Sep 7, 2019; 25(33): 4985-4998
Published online Sep 7, 2019. doi: 10.3748/wjg.v25.i33.4985
Table 6 Independent factors for complete response at 12 mo of antiviral therapy in 232 patients who were treated with nucleos(t)ide analogues
Complete response (n = 199)Incomplete response (n = 33)Univariate
Multivariate
OR95%CIP valueOR95%CIP value
Gender (male)130 (65.3%)20 (60.6%)1.225(0.575-2.610)0.600
Age, yr47.3 ± 11.943.6 ± 10.91.028(0.996-1.062)0.087
HBeAg status (positive)106 (53.3%)30 (90.9%)0.114(0.034-0.386)< 0.0010.438(0.086-2.226)0.320
HBV-DNA, log10 IU/mL5.97 ± 1.407.69 ± 1.130.402(0.290-0.559)< 0.0010.185(0.083-0.412)< 0.001
qHBsAg, log10 IU/mL3.46 ± 0.573.89 ± 0.740.270(0.134-0.544)< 0.0011.492(0.501-4.447)0.473
AST, IU/L94.6 ± 69.583.0 ± 47.21.003(0.997-1.009)0.361
ALT, IU/L103.5 ± 92.791.6 ± 57.51.002(0.997-1.006)0.474
Total bilirubin, mg/dL0.95 ± 0.570.76 ± 0.302.201(0.964-5.024)0.061
Albumin, g/dL4.06 ± 0.534.14 ± 0.440.743(0.351-1.573)0.438
Prothrombin time, INR1.05 ± 0.161.01 ± 0.108.323(0.444-155.931)0.156
Platelet count, × 103/mm3164.6 ± 63.8182.6 ± 53.00.995(0.990-1.001)0.128
Significant fibrosis105 (52.8%)13 (39.4%)1.718(0.810-3.644)0.158
Liver cirrhosis58 (29.1%)6 (18.2%)1.851(0.726-4.720)0.197
HCC33 (16.6%)3 (9.1%)1.988(0.573-6.899)0.279
High genetic barrier180 (90.5%)12 (36.4%)16.579(7.069-38.882)< 0.00182.076(14.945-450.760)< 0.001
Pre-existing rtM204I9 (4.5%)8 (24.2%)0.148(0.052-0.419)< 0.0010.014(0.002-0.096)< 0.001